|
|||||
|
|
Sodium‐glucose co‐transporter type‐2 inhibitors: pharmacology and peri‐operative considerations |
|
| Authors: | D A Milder T Y Milder P C A Kam |
| Affiliation: | 1. Concord Repatriation Hospital, Hospital Road, Concord, NSW, Australia;2. St. Vincent's Hospital, Darlinghurst, NSW, Australia;3. University of Sydney, Royal Prince Alfred Hospital, Camperdown, NSW, Australia |
| Abstract: | Sodium‐glucose co‐transporter 2 (SGLT2) inhibitors are an emerging class of oral hypoglycaemic agents with therapeutic benefits beyond better glycaemic control. A major concern of the sodium‐glucose co‐transporter 2 inhibitors is their propensity to cause euglycaemic ketoacidosis in the peri‐operative period and the potential for this critical diagnosis to be delayed or missed entirely. This review attempts to collate the case reports of sodium‐glucose co‐transporter 2 inhibitor ketoacidosis associated with surgery to highlight and put a perspective on this peri‐operative issue. Preventive strategies and the management of the ketoacidosis are discussed. |
| Keywords: | diabetic ketoacidosis sodium‐glucose co‐transporter 2 (SGLT2) inhibitors |
